health
Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals
Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.
TL;DR
- Novo Nordisk is actively seeking deals and acquisitions to broaden its drug pipeline.
- The CEO aims to help hundreds of millions of patients by expanding the company's offerings.
- Concerns about the robustness of Novo Nordisk's pipeline exist, but the CEO disagrees.
- Promising drug candidates include CagriSema and zenagamtide.
- Novo Nordisk's Wegovy pill performed well, leading to raised full-year profit guidance.